Salmonella Enterica Subsp. Enterica Serovar Typhi

Dosage depends strictly on the formulation prescribed by your healthcare provider:

• Oral Live-Attenuated Vaccine (Ty21a): The standard regimen consists of four capsules. One capsule is taken every other day (e.g., days 1, 3, 5, and 7). The entire series must be completed at least one week before potential exposure to S. Typhi. A booster dose is typically recommended every 5 years for continued high-risk exposure.
• Injectable Polysaccharide Vaccine (Vi): A single 0.5 mL (25 mcg) dose is administered intramuscularly. This should be given at least two weeks before potential exposure. A booster dose is recommended every 2 years if the risk of infection persists.

• Oral Live-Attenuated Vaccine: Approved for children 6 years of age and older. The dosage is the same as the adult regimen (4 capsules). It is NOT recommended for children under 6 years old due to the difficulty of swallowing the capsule whole and lack of safety data in younger cohorts.
• Injectable Polysaccharide Vaccine: Approved for children 2 years of age and older. A single 0.5 mL dose is administered. It is generally not effective in children under 2 years old because their immune systems do not respond well to polysaccharide antigens.
• Typhoid Conjugate Vaccine (TCV): Some newer versions are approved for infants as young as 6 months, though availability varies by region.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the antigens are not cleared via primary renal filtration. However, the patient's overall health should be assessed.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The processing of bacterial antigens does not rely on hepatic metabolic pathways.

Elderly Patients

Clinical studies have not identified significant differences in safety or efficacy between elderly and younger patients. However, the immune response may be slightly diminished in the very elderly due to immunosenescence (age-related decline in immune function).

For the Oral Vaccine (Ty21a):

1. 1Storage: Capsules MUST be kept refrigerated (2°C to 8°C / 36°F to 46°F). Do not freeze.
2. 2Timing: Take the capsule approximately one hour before a meal with a cold or lukewarm drink (not exceeding body temperature). Do NOT take with alcohol.
3. 3Administration: Swallow the capsule whole. Do not chew, crush, or dissolve the capsule, as the enteric coating is vital for protecting the live bacteria from stomach acid.
4. 4Schedule: Strictly follow the 'every other day' schedule. Set a calendar reminder to ensure no doses are missed.

For the Injectable Vaccine (Vi):

1. 1Administered by a healthcare professional, usually in the deltoid muscle of the upper arm.

If you miss a dose of the oral vaccine, contact your healthcare provider. Usually, the schedule is simply shifted, but if a significant delay occurs, the entire series may need to be restarted to ensure adequate immunity. Do not take two capsules at once to make up for a missed dose.

An overdose of the oral vaccine (e.g., taking more than one capsule at a time) is unlikely to cause serious harm but may increase the risk of gastrointestinal side effects like nausea or abdominal cramping. In the event of an accidental ingestion of multiple capsules, monitor for severe GI distress and contact a poison control center or your doctor.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip the series without medical guidance.

Side effects vary based on the route of administration. For most patients, these effects are mild and resolve within 24 to 48 hours.

• Injection Site Reactions (Injectable form): Pain, redness (erythema), and swelling at the site of the shot are very common. This typically feels like a dull ache in the arm.
• Gastrointestinal Symptoms (Oral form): Abdominal pain, nausea, and vomiting may occur as the live bacteria interact with the gut lining.
• Headache: A general 'heavy' feeling or throbbing in the head is frequently reported after both the oral and injectable versions.
• Fever: A low-grade fever (usually under 101°F) is a sign that the immune system is responding to the vaccine.

• Diarrhea: Loose stools may occur following the oral vaccine.
• Malaise: A general feeling of discomfort, fatigue, or 'feeling under the weather.'
• Myalgia: Generalized muscle aches, similar to the early stages of a cold.
• Urticaria: A mild skin rash or hives may appear on the trunk or limbs.

• Severe GI Distress: Intense cramping or persistent vomiting.
• Arthralgia: Joint pain without swelling.
• Paresthesia: Tingling or 'pins and needles' sensations, though this is extremely rare and usually transient.

While vaccines containing Salmonella Enterica Subsp. Enterica Serovar Typhi are generally very safe, serious reactions can occur.

> Warning: Stop taking Salmonella Enterica Subsp. Enterica Serovar Typhi and call your doctor immediately if you experience any of these:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face or throat, rapid heartbeat, dizziness, and a widespread rash. This is a medical emergency.
• High Fever: A temperature exceeding 103°F (39.4°C) or a fever that does not respond to acetaminophen.
• Severe Abdominal Pain: Sharp, localized pain that may indicate an unusual reaction in the intestinal tract.
• Neurological Changes: Confusion, extreme lethargy, or seizures (extremely rare).

There are no known long-term chronic side effects associated with the typhoid vaccine. The vaccine components are cleared from the body quickly, and the immune memory created is the only persisting effect. Unlike the actual disease, the vaccine does not lead to a chronic carrier state.

There are currently no FDA Black Box Warnings for Salmonella Enterica Subsp. Enterica Serovar Typhi vaccines. These products have a long-standing safety profile when used according to the labeled instructions. However, the lack of a black box warning does not mean the vaccine is without risk, particularly for those with contraindications.

Report any unusual symptoms or side effects that persist for more than three days to your healthcare provider. You may also report vaccine side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving a vaccine containing Salmonella Enterica Subsp. Enterica Serovar Typhi, it is crucial to understand that no vaccine is 100% effective. Patients should continue to practice safe 'food and water' habits (boil it, cook it, peel it, or forget it) while traveling in endemic areas. The vaccine protects against S. Typhi but does not protect against Salmonella Paratyphi or other causes of food poisoning.

No FDA black box warnings for Salmonella Enterica Subsp. Enterica Serovar Typhi.

• Allergic Reactions: Patients with a known hypersensitivity to any component of the vaccine (including gelatin or lactose in the oral form) should not receive it. Anaphylaxis, though rare, is a risk with any biological product.
• Immunosuppression: The oral vaccine (Ty21a) contains live bacteria. It should not be administered to individuals with suppressed immune systems, such as those with HIV/AIDS, certain cancers (leukemia, lymphoma), or those taking immunosuppressive drugs (chemotherapy, high-dose steroids, or biologics). There is a theoretical risk of the attenuated bacteria causing systemic illness in these patients.
• Acute Illness: Administration should be postponed in individuals suffering from an acute febrile illness or a gastrointestinal infection until they have fully recovered.
• Antibiotic Interference: For the oral vaccine, recent or current use of antibiotics can kill the live vaccine bacteria before they can trigger an immune response.

No routine laboratory monitoring (like blood counts) is required after vaccination. However, patients should be monitored for 15–30 minutes following an injection to watch for immediate allergic reactions. For the oral series, patients should self-monitor for any severe gastrointestinal symptoms.

There is no evidence that Salmonella Enterica Subsp. Enterica Serovar Typhi affects the ability to drive or operate heavy machinery. If you experience dizziness or significant fatigue after vaccination, wait until these symptoms pass before engaging in such activities.

Alcohol should be avoided when taking the oral Ty21a vaccine. Alcohol can potentially damage the live-attenuated bacteria in the gut, rendering the vaccine ineffective. It is best to avoid alcohol on the days you are taking the capsules.

If the oral series is discontinued before all four doses are taken, the patient will likely not achieve protective immunity. There is no 'withdrawal' syndrome, but the clinical consequence is a lack of protection against typhoid fever.

> Important: Discuss all your medical conditions, especially any history of stomach problems or immune system disorders, with your healthcare provider before starting Salmonella Enterica Subsp. Enterica Serovar Typhi.

• Antibiotics and Sulfonamides: These drugs can inhibit the growth of the live S. Typhi bacteria in the oral vaccine (Ty21a). The oral vaccine should not be started until at least 72 hours after the last dose of an antibiotic. Conversely, antibiotics should not be started for at least 7 days after the last dose of the oral vaccine.
• Certain Antimalarials: Drugs like Proguanil can have an antibacterial effect. It is recommended to delay the start of Proguanil for 3 days after the last dose of the oral typhoid vaccine.

• Immunosuppressants: Drugs such as cyclosporine, tacrolimus, or TNF-blockers (e.g., adalimumab) may reduce the efficacy of both the oral and injectable vaccines. In the case of the oral live vaccine, there is an increased risk of infection from the vaccine strain itself.
• Chemotherapy: Patients undergoing active chemotherapy should wait until their immune system has recovered (usually 3 months post-treatment) before receiving the live vaccine.

• Other Live Vaccines: While the oral typhoid vaccine can often be given simultaneously with other live vaccines (like Yellow Fever or MMR), some providers prefer to space them by 4 weeks to ensure a maximum immune response to each. Always check with your doctor regarding the specific combination.
• Mefloquine: While generally considered safe to take with the oral vaccine, some studies suggest a potential for minor interference. Most guidelines allow for simultaneous use, but monitoring is advised.

• Hot Liquids: Taking the oral capsule with hot tea, coffee, or soup can kill the live bacteria. Only use cold or lukewarm water/milk.
• Food Timing: Taking the oral vaccine on a full stomach may lead to increased gastric acid production, which can degrade the capsule prematurely. Always take it 1 hour before a meal.

There are no well-documented interactions between Salmonella Enterica Subsp. Enterica Serovar Typhi and common herbal supplements like St. John's Wort or Ginkgo. However, any supplement that affects gut motility or gastric pH (like high-dose apple cider vinegar) should be used with caution during the oral series.

• Widal Test: Vaccination may cause a false-positive result on the Widal test (a diagnostic test for typhoid fever) for several months after administration. This is because the test detects the same antibodies the vaccine is designed to produce.
• Stool Cultures: The Ty21a strain may be transiently recovered from stool samples for several days after oral vaccination, which should not be confused with an active infection.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you have recently taken antibiotics.

• Severe Allergic Reaction (Anaphylaxis): Anyone who has had a life-threatening allergic reaction to a previous dose of typhoid vaccine or any of its ingredients (e.g., lactose, sucrose, magnesium stearate, gelatin) must never receive it again.
• Immunodeficiency Disorders: Due to the risk of systemic infection from the live-attenuated strain, the oral Ty21a vaccine is absolutely contraindicated in patients with primary or acquired immunodeficiency (e.g., HIV with low CD4 counts, thymic defects).
• Acute Gastrointestinal Illness: The oral vaccine should not be used in patients currently suffering from inflammatory bowel disease (IBD) flares, acute gastroenteritis, or persistent vomiting/diarrhea, as the vaccine will not be absorbed correctly.

• Pregnancy: While not strictly contraindicated, the use of live vaccines in pregnancy is generally avoided unless the risk of infection is extremely high. The injectable polysaccharide vaccine is usually preferred if vaccination is necessary.
• Recent Antibiotic Use: This is a timing-based contraindication for the oral form. The vaccine will not work if antibiotics are present in the system.

There is no known cross-sensitivity between the typhoid vaccine and other common vaccines like Hep A or Influenza. However, patients with a history of sensitivity to 'Enteric Coatings' or specific capsule fillers should be evaluated for potential reactions to the oral formulation.

> Important: Your healthcare provider will evaluate your complete medical history and current immune status before prescribing Salmonella Enterica Subsp. Enterica Serovar Typhi.

Salmonella Enterica Subsp. Enterica Serovar Typhi vaccines are classified as Pregnancy Category C by the FDA. This means that adequate animal reproduction studies have not been conducted, and it is unknown whether the vaccine can cause fetal harm. In practice, the oral live vaccine is typically avoided during pregnancy due to the theoretical risk of the live bacteria. The injectable polysaccharide vaccine is considered the safer option if a pregnant woman must travel to a high-risk typhoid area. The decision should be based on a careful risk-benefit analysis by a physician.

It is not known whether the antigens or antibodies from the typhoid vaccine are excreted in human milk. However, since the vaccine components are not absorbed into the bloodstream in large quantities (especially the oral form), the risk to a nursing infant is considered negligible. Breastfeeding is not a contraindication to receiving either form of the vaccine.

• Oral Vaccine (Ty21a): Safe and effective for children aged 6 years and older. It is not approved for younger children.
• Injectable Vaccine (Vi): Safe and effective for children aged 2 years and older.
• Growth and Development: There is no evidence that these vaccines impact the growth or long-term development of children.

Clinical trials included a limited number of subjects aged 65 and over. While the vaccine is safe for the elderly, the magnitude of the immune response (antibody titers) may be lower than in younger adults. Elderly patients with multiple comorbidities or those on polypharmacy should be screened for potential drug interactions, particularly with immunosuppressive medications.

No dose adjustment is required. The vaccine is not cleared by the kidneys. However, patients with end-stage renal disease (ESRD) may have a blunted immune response to the vaccine.

No dose adjustment is required. The liver does not play a primary role in the processing of these bacterial antigens.

> Important: Special populations, particularly the immunocompromised and the elderly, require individualized medical assessment before vaccination.

Salmonella Enterica Subsp. Enterica Serovar Typhi vaccines induce active immunity.

• Ty21a (Oral): This strain is a 'rough' mutant of S. Typhi. It lacks the enzyme UDP-galactose-4-epimerase, leading to the accumulation of toxic metabolites if it tries to build its cell wall, resulting in bacterial lysis. Before dying, it stimulates the Gut-Associated Lymphoid Tissue (GALT). This induces a localized sIgA response and a systemic Th1-type cellular immune response.
• Vi Polysaccharide (Injectable): The Vi antigen is a linear homopolymer of poly-alpha-1,4-2-deoxy-2-acetylamino-galacturonic acid. It is a T-cell independent antigen that directly stimulates B-cells to produce IgG antibodies. These antibodies prevent the bacteria from using the Vi capsule to hide from the host's immune system.

• Onset of Action: Protective antibody levels are generally achieved 1 to 2 weeks after the completion of the oral series or the single injection.
• Duration of Effect: Immunity is not lifelong. The oral vaccine provides protection for approximately 5 years, while the injectable polysaccharide vaccine provides protection for about 2 years.
• Efficacy: The vaccines are approximately 50% to 80% effective in preventing typhoid fever, depending on the population and the level of exposure.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Immunological) |

| Protein Binding | N/A |

| Half-life (Antigen) | Several days to weeks |

| Tmax (Antibody) | 14–28 days |

| Metabolism | Intracellular Proteolysis |

| Excretion | Fecal (Live) / Reticuloendothelial (Subunit) |

• Molecular Formula: N/A (Complex Biological Structure)
• Description: The Ty21a strain is a live, attenuated bacterium. The Vi antigen is a purified capsular polysaccharide extracted from the S. Typhi Ty2 strain.
• Solubility: The injectable form is a clear, colorless aqueous solution.

Salmonella Enterica Subsp. Enterica Serovar Typhi belongs to the class of Bacterial Vaccines (Inactivated or Live-Attenuated). It is distinct from toxoid vaccines (like Tetanus) or viral vaccines (like Polio).